129 related articles for article (PubMed ID: 19995649)
1. Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women.
Harichand-Herdt S; Ramalingam SS
Semin Oncol; 2009 Dec; 36(6):572-80. PubMed ID: 19995649
[TBL] [Abstract][Full Text] [Related]
2. Molecular selection trumps clinical selection.
Shepherd FA
J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
[No Abstract] [Full Text] [Related]
3. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Boldrini L; Alì G; Gisfredi S; Ursino S; Baldini E; Melfi F; Lucchi M; Comin CE; Maddau C; Tibaldi C; Camacci T; Servadio A; Mussi A; Fontanini G
Oncol Rep; 2009 Oct; 22(4):683-91. PubMed ID: 19724844
[TBL] [Abstract][Full Text] [Related]
4. Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
Zhang Y; Wang Q; Han ZG; Shan L
Asian Pac J Cancer Prev; 2013; 14(5):2879-83. PubMed ID: 23803047
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Yokoyama Y; Sonobe M; Yamada T; Sato M; Menju T; Aoyama A; Sato T; Chen F; Omasa M; Date H
Int J Clin Oncol; 2015 Dec; 20(6):1122-9. PubMed ID: 25953679
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
[TBL] [Abstract][Full Text] [Related]
7. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
[TBL] [Abstract][Full Text] [Related]
8. Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases.
Sharma A; Tan TH; Cheetham G; Scott HS; Brown MP
J Thorac Oncol; 2012 May; 7(5):941-2. PubMed ID: 22722798
[No Abstract] [Full Text] [Related]
9. Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Izumi H; Touge H; Igishi T; Makino H; Nishii-Ito S; Takata M; Nakazaki H; Ueda Y; Matsumoto S; Kodani M; Kurai J; Takeda K; Sakamoto T; Yanai M; Tanaka N; Nirodi CS; Shimizu E
Int J Oncol; 2015 Mar; 46(3):989-98. PubMed ID: 25573239
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.
Kaneda H; Tamura K; Kurata T; Uejima H; Nakagawa K; Fukuoka M
Lung Cancer; 2004 Nov; 46(2):247-54. PubMed ID: 15474673
[TBL] [Abstract][Full Text] [Related]
11. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Stinchcombe TE; Ramalingam SS
Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
[No Abstract] [Full Text] [Related]
12. Gefitinib for non-small cell lung cancer patients with liver cirrhosis.
Kim YH; Mio T; Mishima M
Intern Med; 2009; 48(18):1677-9. PubMed ID: 19755773
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
[TBL] [Abstract][Full Text] [Related]
14. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.
Chang GC; Tsai CM; Chen KC; Yu CJ; Shih JY; Yang TY; Lin CP; Hsu JY; Chiu CH; Perng RP; Yang PC; Yang CH
J Thorac Oncol; 2006 Jul; 1(6):520-5. PubMed ID: 17409911
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
[TBL] [Abstract][Full Text] [Related]
18. The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.
Watanabe M; Oizumi S; Kiuchi S; Yamada N; Yokouchi H; Fukumoto S; Harada M
Intern Med; 2018 Apr; 57(7):993-996. PubMed ID: 29225262
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
Endo K; Sasaki H; Yano M; Kobayashi Y; Yukiue H; Haneda H; Suzuki E; Kawano O; Fujii Y
Oncol Rep; 2006 Sep; 16(3):533-41. PubMed ID: 16865253
[TBL] [Abstract][Full Text] [Related]
20. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
